Retinal Biologics Market Research Report, By Drug Class (TNF-α Inhibitor and VEGF-A Antagonist), Indication (Macular Degeneration, Diabetic Retinopathy and Uveitis), Distribution Channel (Hospitals and Clinics, Pharmacies) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2027

Retinal Biologics Market Forecast

Retinal Biologics Market is expected to hold a value of about USD 34,891.44 Million by 2027 and is projected to register a CAGR of 11.5% from 2020 to 2027.

Market Synopsis

Retinal biologics are bioengineered molecules that are implanted inside the eyes to heal chronic retinal diseases. There are a large number of different market player for retinal biologics that dominates the market, which includes F. Hoffmann-La Roche Ltd, AbbVie Inc., Johnson & Johnson Services, Inc., Amgen Inc. and many more. The companies are involved in launching new products, technologies, and are undergo strategic collaboration to develop healthcare produces. For instance, in October 2016, F. Hoffmann-La Roche Ltd announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Lucentis (ranibizumab injection) for the treatment of myopic choroidal neovascularization (mCNV).

Retinal Biologics Market Influencer

The increasing innovation and research activity to develop innovative biologics for eye disease treatment boosts the retinal biologics market growth.

Retinal Biologics Market Drivers

- A growing number of cases with ophthalmic disorders causing chronic retinal diseases across the globe is the primary factor driving the market growth. According to the World Health Organization, globally around 2.2 billion people are having a vision problem. The huge patient population suffering from eye problem supports the market growth.

-  Increasing prevalence of retinal vein occlusion (RVO) and age-related macular degeneration. RVO is the second most common retinal vascular disorder and is a significant cause of visual impairment. Around 11 million people in the US have some form of age-related macular degeneration. This number is expected to increase to nearly 22 million by 2050.

-  The growing R&D activities and product launch support retinal biologics market growth during the forecast period.

Retinal Biologics Market Restraints

• High cost of retinal biologics. The average cost per dose of ranibizumab is USD 2000 versus USD 25 per dose for bevacizumab.


• Adverse effects of biologics that may affect the retinal biologics market growth

Retinal Biologics Market Segmentation

By Drug Class

• TNF-α Inhibitor: It is the fastest-growing market as there is a huge demand for TNF—α inhibition for the treatment of retinal damage and increases corneal wound healing. It is largely used as an alternative to conventional immunosuppressive treatments for non-infectious uveitis. Moreover, the research studies on TNF-a drugs will further enhance segmental growth over the forecasted period.

• VEGF-A Antagonist: It is the largest segment by-product in the retinal biologics market. This biologic is used for the treatment of neovascular age-related macular degeneration. Companies are focusing on developing and launching VEGF for the treatment of eye problems. For instance, in March 2018, F. Hoffmann-La Roche Ltd received the Us FDA approval for Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy. The increasing product approvals and launch of new products drive the segmental retinal biologics market growth.

By Indication

• Macular Degeneration: It is also known as age-related macular degeneration that results in blurred or vision loss. Macular degeneration is a problem with the retina that largely affects the middle-aged or elderly population. According to the World Population Prospects the 2019 revision, reported that by 2050, one in six people across the world will be over age 65 up from one in 11 in 2019. Also projected that the number of persons aged 80 years and above may triple, 426 million in 2050 from 143 million in 2019.

• Diabetic Retinopathy: It is the most common cause of vision loss in people having diabetes. There are around 30 million people affected by diabetic retinopathy in the US. The prevalence of diabetes and the aging population contributes to the drive the retinal biologics market growth.

• Uveitis: Uveitis is a form of eye inflammation that causes swelling, eye redness, pain and destroys eye tissues. It affects the middle layer of tissue in the eyewall causing blurred vision.

• Others: Others include cataract, glaucoma, amblyopia, and strabismus.

By Distribution Channel

• Hospitals and Clinics: The hospitals accounted for the largest market share by distribution channel and expected to register a healthy CAGR during the forecast period. The growth of this segment is attributed to a growth in hospital visits for the diagnosis and treatment of eye disorders.

• Pharmacies: Pharmacies hold the largest market share by distribution channel. There are a large number of pharmacies involved in the distribution of prescribed medications safely and efficiently across the globe that boosts segmental growth.

• Others: The other distribution channel includes online pharmacies.

Retinal Biologics Market By Region

• Americas: Holds the largest market share in the global retinal biologics market. Eye disorders are considered as one of the continuing problems for the US and countries around the world. America accounted for the largest market owing to the rising cases of macular degeneration, diabetic retinopathy, uveitis, and others. Currently, around 196 million people are living with macular degeneration worldwide and expected to increase by 288 million by 2040. The increasing new cases of eye problems in this region rises the demand for retinal biologics products.

• Europe: Europe is the second-largest market for retinal biologics. Growing innovation in the healthcare industry, increasing focus on developing new retinal biologics, and the presence of a large number of healthcare companies in this region enhances the European market growth. In 2017, nearly 22 million people were living with age-related macular degeneration (AMD) in the European Union (EU) and around 22 million people in the five most populous European countries which include Germany, France, the UK, Italy, and Spain.

• Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global retinal biologics market. This region has been witnessing the increasing market growth owing to the increase in research for the development of retinal biologics and the growing prevalence of eye diseases. Also, the rising geriatric population supports the retinal biologics market.

• Middle East & Africa: The Middle East & Africa holds the least market share owing to the limited healthcare infrastructure, lack of awareness and limited resources in this region slows down the market growth. The majority of people living with eye problems are situated in low- and middle- income countries, with an estimated 68% living in sub-Saharan Africa.

Key Players

• Regeneron Pharmaceuticals Inc. (US)


• Ocular Therapeutixc.(US)


• Spark Therapeutics (US)


• Hoffmann-La Roche Ltd (Basel, Switzerland)


• AbbVie Inc. (US)


• Johnson & Johnson Services, Inc. (US)


• Amgen Inc. (US)


• MeiraGTx Limited (US)